[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421315":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":25,"studyPopulation":13,"armGroups":26,"interventions":39,"overallOfficials":52,"centralContacts":62,"locations":68,"responsibleParty":85,"collaborators":13,"id":88,"slug":13,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":13,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":13,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":13,"overallStatus":71,"whyStopped":13,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Tanta University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Number of patients with improved CARS score","the patients with improved CARS score","6 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Role of Bumetanide in Treatment of Autism spectrum disorder in children",[27,33],{"label":28,"type":29,"description":30,"interventionNames":31},"bumetanide group","EXPERIMENTAL","Bumetanide a dose of 0.5 mg twice per day",[32],"Drug: Bumetanide",{"label":34,"type":35,"description":36,"interventionNames":37},"Placebo","PLACEBO_COMPARATOR","Placebo twice daily",[38],"Drug: Placebo",[40,47],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"DRUG","Bumetanide","bumetanide 0.5 mg twice daily",[28],[46],"burinex",{"type":41,"name":34,"description":48,"armGroupLabels":49,"otherNames":50},"placebo tablets twice daily",[34],[51],"Placebo treatment",[53,57,60],{"name":54,"affiliation":55,"role":56},"Osama Elagamy, Prof","Pediatrics Department- Kafr-Elsheikh University","PRINCIPAL_INVESTIGATOR",{"name":58,"affiliation":55,"role":59},"Abeer Salamah, Dr","STUDY_DIRECTOR",{"name":61,"affiliation":55,"role":56},"Esraa Shaker, Msc",[63],{"name":64,"role":65,"phone":66,"phoneExt":13,"email":67},"Sherief Abd-Elsalam, ass. prof.","CONTACT","00201147773440","sheriefabdelsalam@yahoo.com",[69],{"facility":70,"status":71,"city":72,"state":13,"zip":13,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Sherief Abd-Elsalam","RECRUITING","Tanta","Egypt","EG",{"type":76,"coordinates":77},"Point",[78,79],31.00192,30.78847,{"lat":79,"lon":78},[82],{"name":83,"role":65,"phone":84,"phoneExt":13,"email":67},"Sherief Abd-Elsalam, Ass. Prof.","00201009221243",{"type":86,"investigatorFullName":70,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Ass. Prof. Tropical Medicine","100421315",false,"NCT04766177","Role of Bumetanide in Treatment of Autism","Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children","Inclusion Criteria:\n\n1. All patients with ASD diagnosed by CARS rating Scale⩾30.\n2. Age of patients range between (3-12) years.\n\nExclusion Criteria:\n\n* Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).","ALL","3 Years","12 Years",{"count":98,"type":99},80,"ESTIMATED","INTERVENTIONAL",[102],"PHASE3","Role of bumetanide in Autism",[105],"Autism","2021-02-19",{"date":108,"type":109},"2021-02-23","ACTUAL",{"date":111,"type":109},"2021-01-01",{"date":113,"type":99},"2030-12-01",{"name":70,"class":6},1]